Alcon Inc. Investors: Alcon Announces Broad Retail Availability of Pataday Once Daily Relief Extra Strength in the U.S. 1 The drop, formerly prescribed as Pazeo, joins Alcon's over-the-counter ocular allergy portfolio to meet a variety of patient needs The expansion of the Pataday portfolio of products will strengthen Alcon's leadership position in the U.S. eye allergy OTC market Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that Pataday Once Daily Relief Extra Strength ( olopatadine hydrochloride ophthalmic solution 0.7%) is now available in-store and online at U.S. retailers, following its 2020 approval by the Food and Drug Administration (FDA) for sale over-the-counter (OTC). As Alcon's third Rx-to-OTC switch in the past twelve months, Pataday Once Daily Relief Extra Strength joins the #1 selling OTC eye allergy relief brand and is poised to help the company maintain its leadership position in the ocular allergy market.